FDA expands the use of melanoma drug Yervoy

28 Oct 2015

The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb’s skin cancer drug, Yervoy, as an additional therapy for patients with late-stage melanoma. This approval extends Yervoy's use to patients with stage III melanoma, who have a high risk of recurrence after surgery.

Yervoy blocks a molecule known as CTLA-4, which may play a role in slowing down or turning off the immune system, and affects its ability to fight off cancerous cells.

CareAcross-sun

Boxed warning for the adverse events

Due to the potential for fatal adverse reactions and unusual severe side effects with Yervoy, the drug's label carries a boxed warning, which is reserved for the most serious of risks.

Yervoy is administered intravenously. It was originally approved in 2011 to treat late-stage melanoma that cannot be removed by surgery.

Source: Reuters
No Comment